In a report released today, Sami Corwin from William Blair maintained a Buy rating on Solid Biosciences. The company’s shares opened today at $6.06.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics. According to TipRanks, Corwin has an average return of 28.8% and a 58.82% success rate on recommended stocks.
Solid Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $15.60.
Based on Solid Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $39.48 million. In comparison, last year the company had a GAAP net loss of $25.07 million
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
